临床和实验室研究年鉴

  • 国际标准期刊号: 2386-5180
  • 期刊 h 指数: 17
  • 期刊引用分数: 6.26
  • 期刊影响因子: 5.31
索引于
  • Genamics 期刊搜索
  • 中国知网(CNKI)
  • 引用因子
  • 研究期刊索引目录 (DRJI)
  • 普布隆斯
  • 欧洲酒吧
  • 谷歌学术
  • 夏尔巴罗密欧
  • 秘密搜索引擎实验室
分享此页面

抽象的

Post-operative Analgesic Characteristics of Intrathecal Adjuvant Agents Including Ketamine, Fentanyl, Sufentanyl, Neostigmine, Dexmedetomidine, Midazolame and Droperidole and their Effects on Spinal Anesthesia

Abdul Kadir Yektas

Aim: This study was designed to compare the intraoperative, postoperative analgesic characteristics and adverse effects of intrathecal combinations of several adjuvant agents combined with hyperbaric bupivacaine in the cases who underwent spinal anaesthesia.

Materials and methods: 180 cases were randomized to 9 groups of 20 cases (n=20). 15 mg of 0.5% hyperbaric bupivacaine and 0.5 ml of serum physiological were administrated to the control group (group-0). In the other groups, instead of serum physiological: Group-1 (2.5 mg hyperbaric bupivacaine), Group-2 (12.5 mg ketamine), Group-3 (25 μgr Fentanyl), Group-4 (2.5 μg sufentanyl), Group-5 (2 μg dexmedetomidine), Group-6 (250 μg neostigmine), Group-7 (500 μg midazolame), Group-8 (1.25 mg Droperidole) were combined with hyperbaric bupivacaine. Total spinal drug volume was 3.5 ml. Intraoperative and postoperative side effects, time to the first pain, and the characteristics of spinal anaesthesia were recorded.

Results: Intrathecal adjuvant agents had no effects on the characteristics of the spinal anaesthesia (p>0.05). Time to the first pain was similar between the groups (p>0.05). The most common side effect was pruritus in Group-3 and Group-4 (p>0.05), nausea-vomiting in Group-6 (p>0.05), urinary retention in Group-2 and Group-4 (p>0.05), and PSBA in Group-1 and Group-3 (p>0.05).

Discussion: No differences in the time to the first pain were found between intrathecal adjuvant agents. Their effects on the characteristics of spinal anaesthesia were similar. Each adjuvant agent causes specific side effects. However, postoperative analgesic requirement was not considered in our study, and dose-finding studies (which are performed to determine the adjuvant agent doses that cause minimal and maximal side effects) were not performed. Further studies should be performed to evaluate those factors.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证